Výsledky vyhledávání

Phase Ib Trial of Cabazitaxel and Tasquinimod in Men With Heavily Pretreated Metastatic Castration Resistant Prostate Cancer (mCRPC): The CATCH Trial

Autor: Carolyn Winters, Michael S. Humeniuk, Michael R. Harrison, Russell Z. Szmulewitz, Daniel J. George, Elia Martinez, Susan Halabi, Patrick Healy, Andrew J. Armstrong, Julie Kephart, Kelly Mundy

Publikováno v: The Prostate. 77:385-395

BACKGROUND Tasquinimod is an immunomodulating and anti-antiangiogenic oral agent with anti-prostate cancer activity in preclinical studies and in clinical trials of men with metastatic castration resistant prostate cancer (mCRPC), including single ag

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::4238ce5e2558ee7da6365a5d06bbdbdd
https://doi.org/10.1002/pros.23277

Zobrazit plný text záznamu

Phase II trial of the PI3 kinase inhibitor buparlisib (BKM-120) with or without enzalutamide in men with metastatic castration resistant prostate cancer

Autor: Andrew J. Armstrong, Julie Kephart, Patrick Healy, Daniel J. George, Colleen Soleau, Kelly Mundy, Evan Y. Yu, Tomasz M. Beer, Carolyn Winters, Rhonda L. Bitting, Joshi J. Alumkal, Rachel Slottke, Carey Hobbs, Susan Halabi

Publikováno v: European journal of cancer (Oxford, England : 1990). 81

Background Phosphatidylinositol-3-kinase (PI3K) and androgen receptor pathway activation is common in metastatic castration resistant prostate cancer (mCRPC). Buparlisib is an oral, pan-class I PI3 kinase inhibitor. Methods This was a multisite singl

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::06f7ca99d570d0a5a43f9176af01fbe9
https://pubmed.ncbi.nlm.nih.gov/28629596

Zobrazit plný text záznamu

Nurse educators—still challenged by critical thinking

Autor: Sharon A. Denham, Kelly Mundy

Publikováno v: Teaching and Learning in Nursing. 3:94-99

Educators are thwarted by inconsistent critical thinking definitions, poor understandings about measurable ways to teach critical thought processes, and a lack of reliable and valid nursing-specific assessment tools to effectively evaluate student re

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::5cfd11cbeda2e5d574d2d7ee21dd992f
https://doi.org/10.1016/j.teln.2008.02.007

Zobrazit plný text záznamu

A phase 2 multimodality trial of docetaxel/prednisone with sunitinib followed by salvage radiation therapy in men with PSA recurrent prostate cancer after radical prostatectomy

Publikováno v: Prostate cancer and prostatic diseases. 19(1)

In men with high Gleason PC and rapid PSA progression after surgery, failure rates remain unacceptably high despite salvage radiation. We explored a novel multimodality approach of docetaxel with anti-angiogenic therapy before salvage radiotherapy (R

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::690787b24e4e1585a68305504b68c073
https://pubmed.ncbi.nlm.nih.gov/26754260

Zobrazit plný text záznamu

A Double Blind, Randomized, Neoadjuvant Study of the Tissue effects of POMx Pills in Men with Prostate Cancer Prior to Radical Prostatectomy

Autor: David Heber, Serina A. King, Yanjun Zhang, Yusheng Jin, Patricia Creel, Helen Fedor, Jianyu Rao, Allan J. Pantuck, Hong Wu, Nils Kroeger, Kelly Mundy, Susan Kerkoutian, Michael A. Carducci, Robin Gurganus, Stephen J. Freedland, Alan W. Partin, Yunfeng Li

Publikováno v: Cancer prevention research (Philadelphia, Pa.), vol 6, iss 10

Pomegranates slow prostate cancer xenograft growth and prolong prostate-specific antigen (PSA) doubling times in single-arm human studies. Pomegranates' effects on human prostate tissue are understudied. We hypothesized that orally administered pomeg

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::91abf01e24cf797eafea3e9e820491a0
https://europepmc.org/articles/PMC3806642/

Zobrazit plný text záznamu

Phase Ib trial of cabazitaxel and tasquinimod in men with heavily pretreated metastatic castration resistant prostate cancer (mCRPC): The CATCH trial

Autor: Elia Martinez, Kelly Mundy, Susan Halabi, Andrew J. Armstrong, Russell Z. Szmulewitz, Patrick Healy, Daniel J. George, Carolyn Winters, Michael R. Harrison

Publikováno v: Journal of Clinical Oncology. 34:190-190

190 Background: Cabazitaxel resistance develops within a few months of treatment initiation in most men with mCRPC in post-docetaxel, and thus combination therapy with other active agents may improve outcomes. Tasquinimod is an oral immunomodulatory

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::94696fb4ae0bbb6f15b2c2e1170fff27
https://doi.org/10.1200/jco.2016.34.2_suppl.190

Zobrazit plný text záznamu

Phase Ib trial of docetaxel, prednisone, and pazopanib, in men with metastatic castration resistant prostate cancer (mCRPC)

Autor: Patrick Healy, Kelly Mundy, Daniel J. George, Sarah Gemberling, Carolyn Winters, Andrew J. Armstrong, Michael R. Harrison, Russell Z. Szmulewitz, Susan Halabi

Publikováno v: Journal of Clinical Oncology. 34:275-275

275 Background: Docetaxel prednisone (DP) is a standard of care for men with metastatic castrate resistant prostate cancer (mCRPC) with median progression-free survival (PFS) of 4-6 months and overall survival (OS) of 19 months, supporting a need for

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::12dfee4746440f726c13841fee691220
https://doi.org/10.1200/jco.2016.34.2_suppl.275

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání